Peter discusses the grim reality faced by patients with aggressive cancers, highlighting that a significant percentage maintain a quality of life despite limited survival expectations. He explains the complexities of treatment options, including the use of previously ineffective drugs in clinical trials, and the ethical considerations of patient enrollment in studies where hope for effective treatment is crucial.
